Alpha DNA Investment Management’s Vertex Pharmaceuticals VRTX Stock Holding History

Alpha DNA Investment Management’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q1	–	Sell	-1,947	Closed	-$792K	–	253
2023 Q4	$792K	Buy	+1,947	New	+$719K	0.31%	69
2023 Q1	–	Sell	-4,615	Closed	-$1.33M	–	208
2022 Q4	$1.33M	Buy	+4,615	New	+$1.41M	0.47%	53
2021 Q2	–	Sell	-252	Closed	-$54K	–	645
2021 Q1	$54K	Sell	252 -19	-7%	-$4.17K	0.06%	162
2020 Q4	$64K	Buy	+271	New	+$62.2K	0.07%	151

Other funds holding VRTX

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

Alpha DNA Investment Management's VRTX Position: Q1 2024 in Review

Alpha DNA Investment Management sold out of Vertex Pharmaceuticals (VRTX) in Q1 2024, closing a stake of 1,947 shares — an estimated $792K sold.

Alpha DNA Investment Management first reported a position in VRTX in Q4 2020 and held it in 4 quarters. The position peaked at $1.33M in Q4 2022. 1,493 funds tracked by Wall St. Rank hold VRTX as of Q1 2024.

Alpha DNA Investment Management reported no remaining Vertex Pharmaceuticals position as of Q1 2024 after selling out during the quarter.
Alpha DNA Investment Management sold 1,947 Vertex Pharmaceuticals shares in Q1 2024, an estimated $792K.
Alpha DNA Investment Management first reported a position in Vertex Pharmaceuticals in Q4 2020 and held it in 4 quarters.
Alpha DNA Investment Management's Vertex Pharmaceuticals position peaked at $1.33M in Q4 2022.
1,493 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2024.

Based on Alpha DNA Investment Management's 13F filing for Q1 2024, filed 15 May 2024.